InVivo Therapeutics Appoints Pamela Stahl as Chief Commercial Officer
InVivo Therapeutics Holdings Corp. (NVIV) today announced the appointment of Pamela Stahl to the newly-created
position of Chief Commercial Officer (CCO), effective September 14, 2016. In this role, she will be responsible for building a
comprehensive global commercial strategy that includes developing the company’s sales, reimbursement, and marketing strategies
across key market segments to ensure a clear path for growth.
Prior to joining InVivo, Ms. Stahl served for 10 years in various roles of increasing responsibility at UnitedHealthcare, most
recently as Chief Executive Officer, Community Health Plan of Wisconsin. In that role, she was responsible for the largest Medicaid
business in the state, providing healthcare benefits and services for over 160,000 Wisconsin residents. Ms. Stahl also held other
Senior Vice President roles at UnitedHealthcare with responsibilities for the Office of the Consumer; Sales Operations and
Organizational Effectiveness; the Women’s Health Line of Service; and Consumer Marketing.
Mark Perrin, Chief Executive Officer and Chairman, said, “We are delighted to be bringing such an experienced and seasoned
leader to InVivo at this pivotal time in the company’s history. We are progressing through our clinical development program and
it’s imperative that we further develop the market for the Neuro-Spinal Scaffold™ as we look toward commercialization. Pam
brings three essential skills and experiences: reimbursement, building commercial organizations, and patient advocacy. She has
decades of experience in the industry, having worked at all levels of a commercial organization, and I am confident she will be a
tremendous asset to the company.”
Prior to UnitedHealthcare, Ms. Stahl was Vice President, Sales and Commercial Operations for Orphan Medical, Inc. from 2001 to
2006. She built and supervised a specialty sales force and established the sales operation function, implemented a risk management
program, and created the patient affairs department. Before that, she served as Vice President, Sales and Marketing for American
TeleCare, Inc. From 1992 until 2000 she held various sales and marketing roles of increasing responsibility at AstraZeneca,
including Regional Marketing Manager, Account Team Leader, Customer Unit Director, Product Optimization Leader, and Regional Sales
Director. Ms. Stahl began her sales career at Merck & Co. Inc.
Ms. Stahl has been a contributing member of many organizations including the National Organization for Rare Diseases Corporate
Council, National Association of Drug Diversion Investigators, National Association of State Controlled Substances Authorities,
National Stakeholder Workgroup for Childbirth Connection, and the UnitedHealthcare Women’s Health Scientific Advisory Board
(Chair). She holds a Bachelor of Arts in Biology from St. Olaf College.
About The INSPIRE Study
The INSPIRE Study: InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold™ for Safety and
Neurologic Recovery in Subjects with Complete Thoracic AIS A Spinal Cord Injury, is designed to demonstrate the safety and
probable benefit of the Neuro-Spinal Scaffold™ for the treatment of complete T2-T12/L1 spinal cord injury in support of
a Humanitarian Device Exemption (HDE) application for approval. For more information, refer to https://clinicaltrials.gov/ct2/show/study/NCT02138110.
About the Neuro-Spinal Scaffold™ Implant
Following acute spinal cord injury, surgical implantation of the biodegradable Neuro-Spinal Scaffold within the
decompressed and debrided injury epicenter is intended to support appositional healing, thereby reducing post-traumatic cavity
formation, sparing white matter, and allowing neural regeneration across the healed wound epicenter. The Neuro-Spinal
Scaffold, an investigational device, has received a Humanitarian Use Device (HUD) designation and currently is being evaluated
in the INSPIRE pivotal probable benefit study for the treatment of patients with complete (AIS A) traumatic acute spinal cord
injury.
About InVivo Therapeutics
InVivo Therapeutics Holdings Corp. is a research and clinical-stage biomaterials and biotechnology company with a focus on
treatment of spinal cord injuries. The company was founded in 2005 with proprietary technology co-invented by Robert Langer, Sc.D.,
Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who then was at Boston Children’s Hospital and who
now is affiliated with Massachusetts General Hospital. In 2011, the company earned the David S. Apple Award from the American
Spinal Injury Association for its outstanding contribution to spinal cord injury medicine. In 2015, the company’s investigational
Neuro-Spinal Scaffold received the 2015 Becker’s Healthcare Spine Device Award. The publicly-traded company is headquartered
in Cambridge, MA. For more details, visit www.invivotherapeutics.com.
InVivo Therapeutics Holdings Corp.
Brian Luque, 617-863-5535
Investor Relations
bluque@invivotherapeutics.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20160811005054/en/